March 19, 2020 09:42 AM EDT

FDA unveils guidance for Covid-19 trials

Zachary Brennan

Senior Editor

The FDA on Wednesday issued new final guidance to help sponsors assure the safety of trial participants, maintain compliance with good clinical practice (GCP) and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA unveils guidance for Covid-19 trials

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA un­veils guid­ance for Covid-19 tri­als

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA unveils guidance for Covid-19 trials

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties